Page 1 of 7

Exhibit 8



1	UNITED STATES DISTRICT COURT
2	NORTHERN DISTRICT OF CALIFORNIA
3	BEFORE THE HONORABLE MARILYN HALL PATEL, JUDGE
4	
5	BOARD OF TRUSTEES of the) LELAND STANFORD JUNIOR)
6	UNIVERSITY,)
7	Plaintiff,)
8	v.) NO. C 05-4158 (MHP)
9	ROCHE MOLECULAR SYSTEMS, INC., et al.,
10)
11) Monday, July 30, 2007u
12) (13 pages)
13	TRANSCRIPT OF PROCEEDINGS
14	APPEARANCES:
15	For Plaintiff: Cooley, Godward, Kronish, LLP
16	5 Palo Alto Square 3000 El Camino Real
17	Palo Alto, California 94306 BY: MICHELLE S. RHYU
18	RICARDO RODRIGUEZ BENJAMIN DAMSTEDT
19	For Defendants: Preetz Law Group, LLP
20	1600 Rosencrans Avenue Fourth Floor
21	Manhattan Beach, California 90266 BY: ADRIAN MARY PRUETZ
22	Quinn, Emanuel, LLP
23	555 Twin Dolphin Drive Suite 560
24	Redwood Shores, California 94065 BY: BRIAN C. CANNON
25	
20	

THE COURT: That's in the declarations. And to the extent that it's appropriate to look at those, I will do that.

MS. PRUETZ: But you do not want the witnesses present at the hearing.

THE COURT: I do not want that testimony, no. No. If there's anything that can be useful without essentially -- without it being advocacy, you know, because so much -- what I'm hearing you say about some of this sounds to me like there's going to be an attempt to use it as advocacy. And we know how important various and kinds of treatments are to trying to do something about the AIDS issue. I mean, we all know that. So we don't need to have a drumbeat for that.

What we need to know is what would a person of ordinary skill in the art have known at the time? And a lot of that can be gleaned from the prior art that's submitted, the prior art that was referenced, or -- and also just looking at the claims in the context of the patent itself. We can determine what those terms mean.

It struck me that some of these terms don't even need to be construed.

MS. RHYU: While you're at that point, can we specifically ask about the SK 38 and SK 39 claims, terms, which actually do not appear in any of the asserted claims? Is there a need for us to brief those terms?

THE COURT: Well, I don't know what those terms mean.

But if they're not going to come up because the claims are not 1 2 at issue... MS. RHYU: They are not terms that exist in any of the 3 asserted claims. 4 Then where do they come up? THE COURT: 5 They're going to come up because we have MS. PRUETZ: 6 a challenge for inventorship, and if any of these claim in the 7 8 patent was intent by somebody else -- and we contend that these 9 claims were all invented by somebody else, including the SK claims -- we do need to have a construction on the SK primers 10 in order to -- I mean, we'll have to get it at some point. 11 makes sense to do it at the claim construction conference for 12 the Court to determine inventorship. 13 THE COURT: But do those terms come up in a particular 14 claim? 15 MS. PRUETZ: Yes, they come up in claims, but they do 16 not come up in the asserted claims. They come up in other 17 But if any one of those claims was invented by someone 18 claims. 19 else, the patent's invalid. THE COURT: Well, is that --20 MS. RHYU: Well, the definition that Roche is 21 proposing for those claims is -- Roche is proposing that the 22 Court state that those primers were invented by CETUS 23 employees, and we don't think that's appropriate for claim 24 If the issue is just to state what the component construction.

25

of those primers is, we can certainly lay that out in the 1 2 brief, but it seems unnecessary. THE COURT: Is there any dispute about what SK 38 and 3 SK 39 mean? 4 MS. PRUETZ: SK 38 and SK 39, according to Roche, mean 5 the primer developed by Shirley Kwok, for whom it's named, who 6 7 is a CETUS employee. But since Stanford disputes that, then we 8 have to have a claim construction on it. 9 MS. RHYU: The patent clearly lays out the sequence of 10 the primer, and that defines the primer. So we think that's where the definition should end. The questions about 11 inventorship can be addressed in a later part of this suit. 12 THE COURT: Well, the whole purpose for having claim 13 construction has to do with infringement and interpreting the 14 claims, construing the claims that are asserted as being 15 16 infringed. 17 MS. PRUETZ: I think it's also relevant in the 18 inventorship, your Honor. 19 THE COURT: If there's a separate issue of inventorship, and that can be brought in a separate proceeding. 20 If it needs to be defined in connection with that proceeding, 21 22 then that's appropriate. I'm concerned that this is maybe being used for the 23 purpose of trying to influence and -- in some way a decision 24

25

on -- in construing other claims, or coming to some decision

with respect to infringement. If there's an inventorship issue, why don't you just bring a motion on inventorship and do the discovery that needs to be done on inventorship and make a motion on it and we'll get to it?

MS. PRUETZ: And the Court will construe the claim in the context of that motion? I mean, we certainly don't want it to be suggested later that we didn't propose a claim construction for a claim that needed to be construed.

THE COURT: Not if it's going to be in the context —
let's put it this way: Not if it's going to be in the context
of an inventorship issue. Okay? And if it is not one of the
claims asserted as a claim being — alleged to be infringed,
then I don't find it's necessary to have claim construction.
If it's necessary to come up with some meaning for what, you
know, what was happening in that particular claim on an
inventorship issue, then we'll deal with it in the context of
the inventorship issue, okay?

Already, we're narrowing down the list, and I'm going to narrow it down event more.

MS. RHYU: Great.

THE COURT: You may not say great after I have finished.

MS. RHYU: Back to the value of expert testimony.

Roche has been insisting on taking depositions of the experts

who may submit declarations in support of the claims

2

3

4 5

6 7

8 9

10

11 12

filing.

13

14

15

16

17

18

19

20

21

22 23

24

25

CERTIFICATE OF REPORTER

I, Connie Kuhl, Official Reporter for the United States Court, Northern District of California, hereby certify that the foregoing proceedings in Case No. C 05-4158 (MHP), BOARD OF TRUSTEES of the LELAND STANFORD JUNIOR UNIVERSITY v. ROCHE MOLECULAR SYSTEMS, INC., et al., were reported by me, a certified shorthand reporter, and were thereafter transcribed under my direction into typewriting; that the foregoing is a true record of said proceedings as bound by me at the time of

The validity of the reporter's certification of said transcript may be void upon disassembly and/or removal from the court file.

Connie Kuhl, RMR, CRR

Wednesday, August 1, 2007